
Insights from 2024 ESGO Annual Meeting
ESGO 2024 Insights: "IMAGYN-050 Trial - Benefit From Atezolizumab in Pts With a Poor Prognostic Ovarian Cancer in 1L Setting"
By
Insights from 2024 ESGO Annual Meeting
FEATURING
Benoit You
By
Insights from 2024 ESGO Annual Meeting
FEATURING
Benoit You
Comments 0
Login to view comments.
Click here to Login